Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

New report details the latest on GLP-1s

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

GLP-1 year two cost effectiveness study abstract

Real-world study of GLP-1 patients continues to deliver leading insights

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...